Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.ase.life | |
Market Cap | 177.02 Cr. | |
Enterprise Value(EV) | 183.52 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 1.79 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 13.04 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.80 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 15.99 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 1.46 | Calculated using Price: 23.30 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 7.66 Cr. | 76,633,296 Shares |
FaceValue | 10 | |
Company Profile | ||
Ambalal Sarabhai Enterprises is a Baroda-based pharmaceutical manufacturing company which was incorporated in 1977. It is one of the company belonging to the Sarabhai Group. The Group's principal activity is manufacture and marketing of pharmaceutical products and bulk drugs. The company's plants are located at Vadodara and Ahmedabad. |
1 Day |
|
+0.43% |
1 Week |
|
-3.72% |
1 Month |
|
-13.70% |
3 Month |
|
-21.81% |
6 Month |
|
-22.72% |
1 Year |
|
-39.32% |
2 Year |
|
+9.13% |
5 Year |
|
+94.33% |
10 Year |
|
+513.16% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | -256.13 | 328.25 | -57.92 | 4.20 | 7.01 | 40.95 | 49.47 | 48.74 | ||
Return on Capital Employed (%) | -17.91 | 10.08 | 107.14 | -11.94 | 16.34 | 13.17 | 27.14 | 40.28 | 45.53 | |
Return on Assets (%) | -9.58 | -3.51 | 25.83 | -10.30 | 0.62 | 0.99 | 7.84 | 15.02 | 21.57 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | -2 | -9 | 39 | 25 | 27 | 31 | 45 | 74 | 120 | 123 | |
Non Curr. Liab. | 59 | 15 | 13 | 6 | 11 | 9 | 5 | 5 | 5 | 9 | |
Curr. Liab. | 155 | 163 | 153 | 124 | 155 | 171 | 133 | 129 | 105 | 101 | |
Minority Int. | 0 | 0 | 0 | 0 | 0 | ||||||
Equity & Liab. | 211 | 169 | 204 | 155 | 193 | 211 | 183 | 208 | 230 | 233 | |
Non Curr. Assets | 144 | 100 | 92 | 82 | 80 | 95 | 79 | 87 | 110 | 115 | |
Curr. Assets | 67 | 68 | 112 | 73 | 114 | 116 | 104 | 121 | 120 | 117 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 211 | 169 | 204 | 155 | 193 | 211 | 183 | 208 | 230 | 233 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 105 | 125 | 132 | 134 | 125 | 152 | 134 | 164 | 197 | 188 | |
Other Income | 3 | 13 | 95 | 6 | 25 | 5 | 24 | 31 | 42 | 14 | |
Total Income | 108 | 137 | 227 | 140 | 150 | 157 | 158 | 194 | 239 | 202 | |
Total Expenditure | -113 | -129 | -145 | -145 | -137 | -146 | -135 | -165 | -172 | -177 | |
PBIDT | -6 | 9 | 82 | -5 | 13 | 11 | 22 | 29 | 67 | 25 | |
Interest | -11 | -10 | -4 | -5 | -3 | -3 | -4 | -3 | -2 | -2 | |
Depreciation | -3 | -5 | -17 | -4 | -2 | -2 | -3 | -2 | -2 | -2 | |
Taxation | -1 | -1 | -14 | -5 | -7 | -4 | -1 | -3 | -7 | -5 | |
Exceptional Items | -15 | ||||||||||
PAT | -20 | -7 | 48 | -19 | 1 | 2 | 15 | 29 | 47 | 16 | |
Minority Interest | |||||||||||
Share Associate | 0 | 0 | 2 | -1 | -2 | ||||||
Other Related Items | |||||||||||
Consolidated Net Profit | -20 | -7 | 48 | -18 | 1 | 4 | 14 | 29 | 47 | 14 | |
Adjusted EPS | -3 | -1 | 6 | -2 | 0 | 1 | 2 | 4 | 6 | 2 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | -3 | 11 | -8 | -75 | 5 | -7 | 19 | -7 | -2 | 11 | |
Cash Fr. Inv. | 0 | -1 | 10 | 80 | -3 | 18 | -9 | 17 | 10 | 5 | |
Cash Fr. Finan. | 3 | -8 | -1 | -3 | -6 | -2 | -6 | -14 | -6 | -19 | |
Net Change | -1 | 2 | 1 | 2 | -4 | 8 | 3 | -4 | 2 | -3 | |
Cash & Cash Eqvt | 6 | 8 | 8 | 10 | 5 | 14 | 17 | 13 | 15 | 12 |
Sat, 04 Feb 2023
Board Meeting Intimation for Approval Of Un-Audited Financial Results For The Quarter And Nine Months Ended December 31 2022 AMBALAL SARABHAI ENTERPRISES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2023 inter alia to consider and approve the Un-audited Financial Results (Standalone & Consolidated) of the Company for the Quarter and nine months ended December 31 2022 and any other matter as the Board of Directors of the Company may decide during the course of the Meeting. This is in pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015.This is for your information and records. |
Fri, 13 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 we enclose herewith a confirmation certificate received from MCS Share Transfer Agent Limited the Registrar and Transfer Agent of the Company for the period ended on 31st December 2022. You are requested to take the above on record. |
Fri, 13 Jan 2023
Board Meeting Outcome for Outcome Of The Board Meeting Held On 13.01.2023 We wish to inform you that the Board of Directors of the Company at their meeting held on 13.01.2023 has approved the Scheme of Arrangement in the nature of Demerger and vesting of the Oncology and Profertility Division of Sarabhai Chemicals (India) Private Limited (SCIPL) into Asence Pharma Private Limited (APPL) subject to the approval of NCLT Shareholders of respective Companies Creditors and other regulatory bodies as applicable under Sections 230 to 232 of the Companies Act 2013 and other applicable provisions of the Companies Act 2013.Disclosure in terms of Regulation 30 of the SEBI (LODR) Regulations 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9 2015 is attached as Annexure I.You are requested to take the same on your record. |
Tue, 07 Feb 2023 |
|
|
|
|
|